Newcastle drug company e-therapeutics says it has received cash payments having reached a set of milestones with a key European partner.
In an update to investors, the firm said it had made significant progress in its work with Belgian company Galapagos NV in searching for medicines for diseases with large unmet medical needs, primarily in inflammation and fibrosis.
The partnership has seen e-therapeutics identify "hit" compounds - the molecules that show a desired activity - using its proprietary computational discovery platform and which have been validated by Galapagos via experiments.
